Switzerland's ADC Therapeutics beats Q1 revenue estimates

Overview

• Switzerland antibody drug conjugate developer's Q1 revenue rose 15%, beating analyst expectations

• Q1 net loss narrowed due to lower operating expenses

• Q1 loss from operations was deeper than analyst expectations

Outlook

• ADC Therapeutics expects LOTIS-5 topline data in 2Q 2026 and full results by year-end

• Company plans to share full LOTIS-7 trial data by end of 2026

• Company expects cash runway at least into 2028

Result Drivers

• PRODUCT SALES VOLUME AND PRICING - Co said higher Q1 revenue was mainly driven by increased product sales volume and higher prices

• LICENSE REVENUE DECLINE - Lower license revenue and royalties due to prior year milestone payment not repeated

• LOWER R&D EXPENSE - Decrease in R&D expense due to discontinued programs and completion of IND-enabling activities for PSMA-targeting ADC

Company press release: ID:nPn2HRHZba

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for ADC Therapeutics SA is $8.00, about 108.9% above its May 1 closing price of $3.83

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.